Ivermectin & Mebendazole in Cancer Patients Shows 84.4% Clinical Benefit

We have all heard about the benefits of using Ivermectin and Mebendazole to treat cancer, and Dr. William Makis has been a great (and relentless) advocate for this. However there has been little formal study into just how effective Ivermectin and Mebendazole are for treating cancer, especially given the politics around Ivermectin. Consequently, research labs and research funders have not wanted to go near it.

However, as more and more post-Covid research is calling into question the ‘treatment dogma’ of that Covid period, so more researchers are striving to uncover the truth. One such researcher is Nicolas Hulscher, who, along with Kelly Victory, MD; James A. Thorp, MD; Peter A. McCullough, MD, MPH; Harvey Risch, MD, PhD (Chairman of the President’s Cancer Panel) and several others have just completed a study which is being hailed as “the largest real-world human analysis to date evaluating Ivermectin and Mebendazole in cancer patients.”

According to Nicolas Hulscher, “…the results of this new study represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

In this real-world prospective clinical program evaluation, a diverse population of cancer patients were prescribed compounded Ivermectin–Mebendazole. At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR), with nearly half of cancer patients (48.4%) reporting either no evidence of disease (32.8%) or tumour regression (15.6%). An additional 36.1% reported disease stabilization.

This means more than four out of five patients reported either improvement or stabilization of their cancer. These results indicate that the inexpensive and safe off-label applications of these medications could be an important complement in the treatment of cancer.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

At approximately six months, outcomes were distributed as follows:

• No Evidence of Disease (NED): 32.8%
• Tumour Regression: 15.6%
• Stable Disease: 36.1%
• Progression: 15.6%

This yields a Clinical Benefit Ratio (CBR) of 84.4%, meaning more than four out of five patients reported either improvement or stabilization of their cancer. Critically, the 48.4% rate of NED + regression represents the strongest signal—indicating that a substantial proportion of patients did not merely stabilize, but reported meaningful reversal of disease burden.

CONCLUSION

This first-ever real-world analysis of an Ivermectin–Mebendazole protocol in human cancer patients provides a compelling signal that demands serious attention. The magnitude, internal consistency, and broad distribution of the observed effects cannot be ignored. We are not observing marginal changes or isolated responses—we are observing widespread self-reported disease control across a diverse cancer population, a substantial proportion of patients reporting complete disappearance of detectable cancer, and sustained adherence with favourable tolerability over time.

By Nicolas Hulscher, MPH

This research is very compelling and clearly indicates the exciting potential of Ivermectin and Mebendazole as an effective cancer treatment. But it is still ‘early days’ and a lot more research and study needs to be done. However, this first study by Hulscher, McCullough and their team is extremely encouraging, and we will continue to follow and report on how it develops – and no doubt how the pro-chemo lobby will try to discredit it!

The main source for this article is: https://www.thefocalpoints.com/p/breaking-largest-real-world-analysis.  The full research paper can be accessed here: https://zenodo.org/records/19455636